TNFRSF9 and neoplasm: The enhanced immune response was primarily mediated by CD8+ T cells that were activated by the anti-CD137 monoclonal antibody and accompanied by a significant enhancement in tumor-specific cytotoxic T lymphocyte (CTLs) activity [30].